Copyright
©The Author(s) 2021.
World J Clin Cases. Apr 26, 2021; 9(12): 2845-2853
Published online Apr 26, 2021. doi: 10.12998/wjcc.v9.i12.2845
Published online Apr 26, 2021. doi: 10.12998/wjcc.v9.i12.2845
Relevant past medical history and interventions | |||
No relevant past medical history | |||
Date | Summaries from Initial and follow-up visits | Diagnostic testing | Interventions |
June 2015 | Left upper limb convulsions, urinary incontinence, nausea, vomiting, and loss of consciousness with no apparent cause | CT examination in a local hospital showed no obvious abnormality, but MRI indicated a space-occupying lesion in the right frontal lobe | Without any treatment |
October 2015 | Headache, limb weakness, and left hemiplegia | Repeat CT suggested a right frontal parietal lobe cerebral hemorrhage | Symptomatic supportive treatment, including carbamazepine 400 mg twice/d orally. However, the patient stopped carbamazepine of his own accord due to aggravated limb weakness |
February 2016 | Final diagnosis: glioblastoma, maximum diameter about 5 cm | Cranial MRI showed that the right frontal parietal lobe was occupied by a mass, identified as a possible high-grade glioma. Hematoxylin-eosin staining showed that the tumor cells diffused and infiltrated. Cells were heteromorphic with mitotic figures, microvessel hyperplasia and palisade necrosis. Tumor cells were immunopositive for glial fibrillary acidic protein immunostaining, and about 70% of tumor cells were positive for Ki-67 | Partial resection and concurrent chemoradiation therapy until April 2016, with 75 mg/m2 TMZ once daily for 45 d combined with focal radiotherapy of 60 Gy administered in 30 fractions |
April 2016 | Intolerable ADRs, including nausea, vomiting, and loss of appetite | None | Discontinued the chemoradiotherapy |
June 2016 | Postoperative review: maximum diameter about 3.5 cm | Enhanced right frontal parietal lobe space-occupying lesion, maximum diameter about 3.5 cm | Kangliu Pill 7.5 g three times/d |
October 2016 | Maximum diameter from about 3.5 to about 2 cm | Enhanced lesion at the junction of the right frontal and parietal lobes, maximum diameter about 2 cm | Continue Kangliu pill 7.5 g three times/d |
April 2019 | Maximum diameter about 1 cm | Enhanced lesion at the junction of the right frontal and parietal lobes, maximum diameter about 1 cm | Continue Kangliu pill 7.5 g three times/d |
Final outcome | |||
The patient’s symptoms of headache, limb weakness, and left hemiplegia were relieved, with no side effects |
- Citation: Sun G, Zhuang W, Lin QT, Wang LM, Zhen YH, Xi SY, Lin XL. Partial response to Chinese patent medicine Kangliu pill for adult glioblastoma: A case report and review of the literature. World J Clin Cases 2021; 9(12): 2845-2853
- URL: https://www.wjgnet.com/2307-8960/full/v9/i12/2845.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v9.i12.2845